E
Entranced98
Guest
Adding local short description: "Experimental drug", overriding Wikidata description "experimental drug candidate"
[td]'''MIS416''' is an [[experimental drug]] developed by [[Innate Immunotherapeutics]] which underwent clinical trials to treat secondary progressive [[multiple sclerosis]]. It is derived from the [[Cutibacterium acnes|bacteria that causes acne]] and targets [[myeloid cells]] through [[TLR9]] and [[NOD2]].<ref name="australiasian bio">{{cite journal|date=October 2013|title=Innate Immunotherapeutics: Acne Offers Real Hope for MS Treatment|journal=Australasian Biotechnology|volume=23|issue=3|page=55|issn=1036-7128}}</ref><ref name=adis>{{cite web |title=Drug Profile: MIS 416 |url=https://adisinsight.springer.com/drugs/800030048 |website=adisinsight.springer.com |date=27 June 2018|accessdate=29 August 2018}}</ref><ref>{{cite web|title=Results Announced from Phase 2 Trial of MIS416|url=https://www.nationalmssociety.org/A...unced-from-Phase-2-Trial-of-MIS416-in|date=27 June 2017|publisher=[[National Multiple Sclerosis Society]]|access-date=8 August 2018|archive-date=8 August 2018|archive-url=https://web.archive.org/web/2018080...om-Phase-2-Trial-of-MIS416-in|url-status=dead}}</ref><ref>{{cite web |title=Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis |url=https://clinicaltrials.gov/ct2/show/NCT02228213 |date=28 August 2014|accessdate=29 August 2018|publisher=[[United States National Library of Medicine]]}}</ref> In one of its first rounds of clinical trials, the drug was shown to be "safe and well tolerated", with 80% of secondary-progressive multiple sclerosis patients exhibiting more than 30% improvement in at least one area of their MS status.<ref name="australiasian bio" /> However, Phase II clinical trials were unable to prove that the drug provided a benefit to patients. It is also being researched as a potential treatment for cancer.[/td] [td][/td]
[td][/td]
Continue reading...
| Line 1: | Line 1: |
[td]
β Previous revision
[/td][td]
[td]{{Short description|Experimental drug}}[/td]
[td]'''MIS416''' is an [[experimental drug]] developed by [[Innate Immunotherapeutics]] which underwent clinical trials to treat secondary progressive [[multiple sclerosis]]. It is derived from the [[Cutibacterium acnes|bacteria that causes acne]] and targets [[myeloid cells]] through [[TLR9]] and [[NOD2]].<ref name="australiasian bio">{{cite journal|date=October 2013|title=Innate Immunotherapeutics: Acne Offers Real Hope for MS Treatment|journal=Australasian Biotechnology|volume=23|issue=3|page=55|issn=1036-7128}}</ref><ref name=adis>{{cite web |title=Drug Profile: MIS 416 |url=https://adisinsight.springer.com/drugs/800030048 |website=adisinsight.springer.com |date=27 June 2018|accessdate=29 August 2018}}</ref><ref>{{cite web|title=Results Announced from Phase 2 Trial of MIS416|url=https://www.nationalmssociety.org/A...unced-from-Phase-2-Trial-of-MIS416-in|date=27 June 2017|publisher=[[National Multiple Sclerosis Society]]|access-date=8 August 2018|archive-date=8 August 2018|archive-url=https://web.archive.org/web/2018080...om-Phase-2-Trial-of-MIS416-in|url-status=dead}}</ref><ref>{{cite web |title=Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis |url=https://clinicaltrials.gov/ct2/show/NCT02228213 |date=28 August 2014|accessdate=29 August 2018|publisher=[[United States National Library of Medicine]]}}</ref> In one of its first rounds of clinical trials, the drug was shown to be "safe and well tolerated", with 80% of secondary-progressive multiple sclerosis patients exhibiting more than 30% improvement in at least one area of their MS status.<ref name="australiasian bio" /> However, Phase II clinical trials were unable to prove that the drug provided a benefit to patients. It is also being researched as a potential treatment for cancer.[/td]Revision as of 14:19, 2 September 2025
[/td][td]'''MIS416''' is an [[experimental drug]] developed by [[Innate Immunotherapeutics]] which underwent clinical trials to treat secondary progressive [[multiple sclerosis]]. It is derived from the [[Cutibacterium acnes|bacteria that causes acne]] and targets [[myeloid cells]] through [[TLR9]] and [[NOD2]].<ref name="australiasian bio">{{cite journal|date=October 2013|title=Innate Immunotherapeutics: Acne Offers Real Hope for MS Treatment|journal=Australasian Biotechnology|volume=23|issue=3|page=55|issn=1036-7128}}</ref><ref name=adis>{{cite web |title=Drug Profile: MIS 416 |url=https://adisinsight.springer.com/drugs/800030048 |website=adisinsight.springer.com |date=27 June 2018|accessdate=29 August 2018}}</ref><ref>{{cite web|title=Results Announced from Phase 2 Trial of MIS416|url=https://www.nationalmssociety.org/A...unced-from-Phase-2-Trial-of-MIS416-in|date=27 June 2017|publisher=[[National Multiple Sclerosis Society]]|access-date=8 August 2018|archive-date=8 August 2018|archive-url=https://web.archive.org/web/2018080...om-Phase-2-Trial-of-MIS416-in|url-status=dead}}</ref><ref>{{cite web |title=Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis |url=https://clinicaltrials.gov/ct2/show/NCT02228213 |date=28 August 2014|accessdate=29 August 2018|publisher=[[United States National Library of Medicine]]}}</ref> In one of its first rounds of clinical trials, the drug was shown to be "safe and well tolerated", with 80% of secondary-progressive multiple sclerosis patients exhibiting more than 30% improvement in at least one area of their MS status.<ref name="australiasian bio" /> However, Phase II clinical trials were unable to prove that the drug provided a benefit to patients. It is also being researched as a potential treatment for cancer.[/td] [td][/td]
[td][/td]
Continue reading...
